Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.
Numakura K, Kobayashi M, Muto Y, Sato H, Sekine Y, Sobu R, Aoyama Y, Takahashi Y, Okada S, Sasagawa H, Narita S, Kumagai S, Wada Y, Mori N, Habuchi T. Numakura K, et al. Among authors: sobu r. Curr Oncol. 2023 Sep 1;30(9):8092-8110. doi: 10.3390/curroncol30090587. Curr Oncol. 2023. PMID: 37754502 Free PMC article. Review.
Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-institutional study in Japan.
Morizane S, Nakane K, Tanaka T, Zennami K, Muraoka K, Ebara S, Miura N, Uemura K, Sobu R, Hoshi A, Taoka R, Sugimoto M, Noma H, Sunada H, Nishiyama H, Habuchi T, Ikeda I, Saika T, Makiyama K, Shiroki R, Masumori N, Koie T, Takenaka A. Morizane S, et al. Among authors: sobu r. Int J Clin Oncol. 2024 Jan;29(1):64-71. doi: 10.1007/s10147-023-02425-8. Epub 2023 Oct 21. Int J Clin Oncol. 2024. PMID: 37864612
Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.
Sobu R, Numakura K, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T. Sobu R, et al. Cancer Med. 2023 Feb;12(4):4100-4109. doi: 10.1002/cam4.5268. Epub 2022 Oct 6. Cancer Med. 2023. PMID: 36200612 Free PMC article.
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Kobayashi M, et al. Among authors: sobu r. Int J Clin Oncol. 2023 Nov;28(11):1530-1537. doi: 10.1007/s10147-023-02394-y. Epub 2023 Aug 8. Int J Clin Oncol. 2023. PMID: 37552353
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K, Sekine Y, Osawa T, Naito S, Tokairin O, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Yamamoto R, Nara T, Saito M, Narita S, Akashi H, Tsuchiya N, Shinohara N, Habuchi T. Numakura K, et al. Among authors: sobu r. Int J Clin Oncol. 2024 May 26. doi: 10.1007/s10147-024-02538-8. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38797782